Who Exports Anastrozole from India — 158 Suppliers Behind a $110.7M Market
India's anastrozole export market is supplied by 158 active exporters who collectively shipped $110.7M across 2,238 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 84.7% market share, followed by ZYDUS LIFESCIENCES LIMITED and EUGIA PHARMA SPECIALITIES LIMITED. The top 5 suppliers together control 96.4% of total export value, reflecting a concentrated market structure.
Top Anastrozole Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading anastrozole exporter from India, holding a 84.7% share of the $110.7M market across 2,238 shipments from 158 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, ZYDUS LIFESCIENCES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, NATCO PHARMA LIMITED — collectively control 96.4% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (84.7%), ZYDUS LIFESCIENCES LIMITED (3.2%), EUGIA PHARMA SPECIALITIES LIMITED (3.2%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (2.8%), NATCO PHARMA LIMITED (2.4%).
Top Anastrozole Exporters from India
Ranked by export value · 158 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED ANASTROZOLE TABLETS USP 1MG - BTANASTROZOLE 1MG TABLETS 28'STARO-ANASTROZOLE FILM COATED TABLETS 1MG | $93.8M | 13 | 84.7% |
| 2 | ZYDUS LIFESCIENCES LIMITED ANASTROZOLE TABLETS USP 1MG - BT | $3.6M | 3 | 3.2% |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED ANASTROZOLE TABLETS USP 1MG - BTANASTROZOLE 1MG TABLETS 28'SANASTROZOLE 1MG TABLETS | $3.5M | 6 | 3.2% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ANYA TABLETS USP 1 MG (PACANYA USP TAB 1MG 3X10B BR EACH TABLET CONTAINS: ANASTROZOLEANYA TABLETS USP 1MG PACK: | $3.1M | 5 | 2.8% |
| 5 | NATCO PHARMA LIMITED ANASTROZOLE TABLETS USP 1MG - BTANASTROZOLE 1MG TABLETS 28'STARO-ANASTROZOLE FILM COATED TABLETS 1MG | $2.7M | 10 | 2.4% |
| 6 | JODAS EXPOIM PRIVATE LIMITED ANASTROZOLE TABLETS 1MGANASTROZOLE TABLETS 1MG 3X10S ALU PVCBLISTER PACKANAROM TABLETS (ANASTROZOLE TABLETS 1 MG | $1.9M | 3 | 1.7% |
| 7 | CADILA HEALTHCARE LTD ANASTROZOLE TABLETS USP 1MG - BT | $475.8K | 1 | 0.4% |
| 8 | CADILA HEALTHCARE LIMITED ANASTROZOLE TABLETS USP 1MG - BT | $234.6K | 1 | 0.2% |
| 9 | HETERO LABS LIMITED ANYA TABLETS USP 1 MG (PACANYA USP TAB 1MG 3X10B BR EACH TABLET CONTAINS: ANASTROZOLEANYA TABLETS USP 1MG PACK: | $207.7K | 4 | 0.2% |
| 10 | STERIL-GENE LIFE SCIENCES PRIVATE LIMITED ANASTROZOLE 1MG TABLETS 28'SANASTROZOLE 1 MG TABLETS | $153.3K | 1 | 0.1% |
| 11 | UNITED BIOTECH PRIVATE LIMITED ARMILON 10 X 10 PACK SIZEANASTROZOLE TABLETS USP 1MG (BRAND: ANASANASTROZOLE TABLETS 1MG TBS | $100.7K | 4 | 0.1% |
| 12 | GLOBELA PHARMA PRIVATE LIMITED ANAROM TABLETS (ANASTROZOLE TABLETS 1 MGANAROM TABLETS PACK : BOX 2X14S SAP CODE : 1117383ARMIDA PACK 3X10'SANASTROZOLE TABLETSUSP 1 MG | $54.4K | 3 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Anastrozole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Warning Letter, August 20 | Yes, as of May 26, 2 | Yes | 59 approvals as of September 2023 | Received FDA warning letter in August 2024; holds WHO-GMP certification since Ma |
| Eugia Pharma Specialities Limited | Warning Letter, August 20 | Unknown | Unknown | 14 approvals as of September 2023 | Received FDA warning letter in August 2024; 14 ANDA approvals by September 2023. |
| Sun Pharmaceutical Industries Limited | Warning Letter, June 2024 | Unknown | Unknown | 10 approvals as of September 2023 | Received FDA warning letter in June 2024; 10 ANDA approvals by September 2023. |
| Natco Pharma Limited | Warning Letter, April 202 | Unknown | Unknown | 4 approvals as of September 2023 | Received FDA warning letter in April 2024; 4 ANDA approvals by September 2023. |
| Cadila Pharmaceuticals Limited | Warning Letter, March 201 | Yes | Yes | Unknown | Received FDA warning letter in March 2014; holds WHO-GMP and EU GMP certificatio |
| Intas Pharmaceuticals Limited | Warning Letter, December | Yes | Yes | Unknown | Received FDA warning letter in December 2022; holds WHO-GMP and EU GMP certifica |
| Jodas Expoim Private Limited | Unknown | Yes | Yes | Unknown | Holds WHO-GMP and EU GMP certifications; no FDA warning letters found. |
| Globela Pharma Private Limited | Unknown | Yes | Unknown | Unknown | Holds WHO-GMP certification; no FDA warning letters found. |
TransData Nexus reviewed the regulatory standing of 8 leading Anastrozole exporters from India. 0 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 4 are EU GMP compliant. 6 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Anastrozole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing, particularly in active pharmaceutical ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, which accommodates over 200 life sciences companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a strategic location for sourcing APIs essential for Anastrozole production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its robust pharmaceutical formulations industry. Ahmedabad is home to leading companies such as INTAS PHARMACEUTICALS LIMITED and Zydus Lifesciences Limited, both significant contributors to Anastrozole exports. Vadodara complements this with a strong manufacturing base, housing numerous pharmaceutical units that specialize in finished formulations. The synergy between these cities provides a comprehensive ecosystem for the production and export of pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, hosts headquarters of major pharmaceutical companies and offers advanced logistics and port facilities. Thane and Raigad districts have developed industrial zones that support pharmaceutical manufacturing and export activities. This region's infrastructure and connectivity facilitate efficient distribution of pharmaceutical products to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as prominent pharmaceutical manufacturing zones, primarily due to favorable tax incentives and supportive government policies. Baddi, in particular, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 pharmaceutical companies. The region's strategic location and cost-effective production capabilities make it an attractive destination for pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: While INTAS PHARMACEUTICALS LIMITED dominates Anastrozole exports, consider engaging with other manufacturers in the Ahmedabad-Vadodara corridor to mitigate supply chain risks.
- Leverage Hyderabad's API Strength: Utilize Hyderabad's expertise in API production to secure high-quality raw materials for Anastrozole manufacturing.
- Optimize Logistics via Mumbai: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to streamline distribution channels and reduce lead times.
- Explore Cost Benefits in Baddi: Assess the cost advantages offered by Baddi's tax incentives and manufacturing capabilities for potential production partnerships.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and optimize the sourcing and distribution of Anastrozole.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Anastrozole exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma announced the acquisition of Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology treatment company, for $355 million. This strategic move aims to enhance Sun Pharma's oncology portfolio and expand its presence in the U.S. market. - IMPACT: This acquisition is expected to strengthen Sun Pharma's position in the oncology sector, potentially leading to increased resources and focus on related products, including Anastrozole.
Impact: This acquisition is expected to strengthen Sun Pharma's position in the oncology sector, potentially leading to increased resources and focus on related products, including Anastrozole.
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business and partners on commercialization
Zydus Lifesciences acquired the Contract Development and Manufacturing Organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. Additionally, Zydus partnered with Agenus to commercialize their molecules in India. - IMPACT: This acquisition and partnership may enhance Zydus' manufacturing capabilities and product offerings, potentially impacting the production and export of Anastrozole.
Impact: This acquisition and partnership may enhance Zydus' manufacturing capabilities and product offerings, potentially impacting the production and export of Anastrozole.
Zydus Lifesciences Limited — Zydus receives USFDA approval for prostate cancer drug
Zydus Lifesciences received approval from the U.S. Food and Drug Administration (USFDA) to manufacture enzalutamide tablets, an androgen receptor inhibitor used for treating prostate cancer. The product will be manufactured at Zydus' facility in Ahmedabad. - IMPACT: The USFDA approval may bolster Zydus' oncology portfolio, potentially influencing the production and export dynamics of related drugs, including Anastrozole.
Impact: The USFDA approval may bolster Zydus' oncology portfolio, potentially influencing the production and export dynamics of related drugs, including Anastrozole.
Common Questions — Anastrozole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which anastrozole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 209 recorded shipments worth $93.8M. ZYDUS LIFESCIENCES LIMITED (111 shipments) and EUGIA PHARMA SPECIALITIES LIMITED (116 shipments) are also established high-volume exporters.
Q How many anastrozole manufacturers are there in India?
India has 158 active anastrozole exporters with a combined export market of $110.7M across 2,238 shipments to 99 countries. The top 5 suppliers hold 96.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for anastrozole from India?
Average FOB unit price: $2.43 per unit, ranging from $0.01 to $100.00. Average shipment value: $49.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 158 verified Indian exporters of Anastrozole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,238 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 99 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,238 Verified Shipments
158 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists